132 related articles for article (PubMed ID: 38423629)
1. Anti-Cancer Effects of CDK4/6 Inhibitor LEE011 and Chemotherapy Drugs on Lymphocytic Leukemia L1210 Cells.
Lin YC; Lin YH; Chang YU; Su YC; Hsieh WC; Chen WH; Lee HM
Anticancer Res; 2024 Mar; 44(3):1121-1130. PubMed ID: 38423629
[TBL] [Abstract][Full Text] [Related]
2. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Aristizabal Prada ET; Nölting S; Spoettl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):58-73. PubMed ID: 28226315
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.
Zhang YX; Sicinska E; Czaplinski JT; Remillard SP; Moss S; Wang Y; Brain C; Loo A; Snyder EL; Demetri GD; Kim S; Kung AL; Wagner AJ
Mol Cancer Ther; 2014 Sep; 13(9):2184-93. PubMed ID: 25028469
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of G
Tao YF; Wang NN; Xu LX; Li ZH; Li XL; Xu YY; Fang F; Li M; Qian GH; Li YH; Li YP; Wu Y; Ren JL; Du WW; Lu J; Feng X; Wang J; He WQ; Hu SY; Pan J
Cancer Cell Int; 2017; 17():35. PubMed ID: 28286417
[TBL] [Abstract][Full Text] [Related]
5. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
6. CDK4/6 Inhibitor LEE011 Is a Potential Radiation-sensitizer in Head and Neck Squamous Cell Carcinoma: An
Tai TS; Lin PM; Wu CF; Hung SK; Huang CI; Wang CC; Su YC
Anticancer Res; 2019 Feb; 39(2):713-720. PubMed ID: 30711949
[TBL] [Abstract][Full Text] [Related]
7. Synergistic and Antagonistic Antiproliferative Effects of Ribociclib (Lee011) and Irinotecan (SN38) on Colorectal Cancer Cells.
Huang CI; Huang YK; Lee HM; Chen JH; Su YC; Lin PM
Anticancer Res; 2023 May; 43(5):1933-1941. PubMed ID: 37097665
[TBL] [Abstract][Full Text] [Related]
8. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
Lee HJ; Lee WK; Kang CW; Ku CR; Cho YH; Lee EJ
Cancer Lett; 2018 Mar; 417():131-140. PubMed ID: 29306020
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.
Pikman Y; Alexe G; Roti G; Conway AS; Furman A; Lee ES; Place AE; Kim S; Saran C; Modiste R; Weinstock DM; Harris M; Kung AL; Silverman LB; Stegmaier K
Clin Cancer Res; 2017 Feb; 23(4):1012-1024. PubMed ID: 28151717
[No Abstract] [Full Text] [Related]
10. Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro.
Jin XF; Spöttl G; Maurer J; Nölting S; Auernhammer CJ
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33807122
[TBL] [Abstract][Full Text] [Related]
11. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
[TBL] [Abstract][Full Text] [Related]
12. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.
Rader J; Russell MR; Hart LS; Nakazawa MS; Belcastro LT; Martinez D; Li Y; Carpenter EL; Attiyeh EF; Diskin SJ; Kim S; Parasuraman S; Caponigro G; Schnepp RW; Wood AC; Pawel B; Cole KA; Maris JM
Clin Cancer Res; 2013 Nov; 19(22):6173-82. PubMed ID: 24045179
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Antiproliferative Effect of Ribociclib (LEE011) and 5-Fluorouracil on Human Colorectal Cancer.
Lin PM; Lee HM; Huang CI; Tai TS; Chen JH; Chen CI; Su YC
Anticancer Res; 2020 Nov; 40(11):6265-6271. PubMed ID: 33109564
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.
Yuan Y; Wen W; Yost SE; Xing Q; Yan J; Han ES; Mortimer J; Yim JH
Sci Rep; 2019 May; 9(1):7509. PubMed ID: 31101835
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer).
Scheinberg T; Kench J; Stockler M; Mahon KL; Sebastian L; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Centenera MM; Butler LM; Horvath LG
BMJ Open; 2020 Jan; 10(1):e033667. PubMed ID: 31988233
[TBL] [Abstract][Full Text] [Related]
16. mTORC1/2 Inhibitor Served as a More Ideal Agent Against the Growth of Mouse Lymphocytic Leukemia Both
Liao HF; Lin YZ; Yu CC; Tai TS; Hung SK; Yang CC; Su YC
Anticancer Res; 2019 Sep; 39(9):4829-4835. PubMed ID: 31519585
[TBL] [Abstract][Full Text] [Related]
17. The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Kim S; Tiedt R; Loo A; Horn T; Delach S; Kovats S; Haas K; Engstler BS; Cao A; Pinzon-Ortiz M; Mulford I; Acker MG; Chopra R; Brain C; di Tomaso E; Sellers WR; Caponigro G
Oncotarget; 2018 Oct; 9(81):35226-35240. PubMed ID: 30443290
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
19. Targeting CDK4/6 in patients with cancer.
Hamilton E; Infante JR
Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
[TBL] [Abstract][Full Text] [Related]
20. A Novel Methoxybenzyl 5-Nitroacridone Derivative Effectively Triggers G1 Cell Cycle Arrest in Chronic Myelogenous Leukemia K562 Cells by Inhibiting CDK4/6-Mediated Phosphorylation of Rb.
Zhang B; Zhang T; Zhang TY; Wang N; He S; Wu B; Jin HX
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
